Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Apple Turns 50: From Garage Startup to AI Crossroads 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
CAMBRIDGE, Mass., Jan. 04, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 11:30 a.m. PT in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
